[Asia Economy Reporter Hyunseok Yoo] Nivek is accelerating new drug development by supplying preclinical stage candidate substances to global pharmaceutical companies for the treatment of lung diseases, including pulmonary fibrosis caused by respiratory diseases.
On the 31st, Nivek announced that following the protein therapeutic production and supply contract signed with a global pharmaceutical company in January, it has supplied preclinical stage candidate substances for new drug development. The supplied candidate substances are planned to be used for new drug development related to the treatment of lung diseases, including pulmonary fibrosis, and heart diseases.
A Nivek official stated, "This candidate substance supply is a product that has successfully passed a thorough pre-verification process by a global pharmaceutical company as a protein therapeutic based on vector design and purification technology." He added, "Following this first supply, the second supply order has already been completed, and scale-up work is underway to prepare for future supply volume expansion." He continued, "Beyond the substance supply contract, discussions are ongoing regarding contracts related to the commercialization of candidate substances as a follow-up business, and it is highly likely that significant long-term contracts with global pharmaceutical companies will continue."
In August of last year, Nivek completed the establishment of a biologics lab based on advanced facilities. At the Nivek Biologics Lab, not only protein expression but also drug-antibody conjugate new drug development based on chemical bonding is underway.
Through this regular shareholders' meeting, Nivek also obtained approval for an amendment to its articles of incorporation to add the protein therapeutic business as a business purpose. The company explained that it plans to expand from a peptide platform to the protein therapeutic business, thereby fully activating the growth momentum of the biopharmaceutical company.
Nivek's protein therapeutic business is known as an extension of peptide platform technology. Based on the know-how accumulated through long-term research and development of peptide pharmaceuticals and drug delivery technologies, Nivek plans to continue growth centered on the peptide-based business and protein therapeutic business, which are new growth engines.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
